At BioSpace, Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced positive results from a preclinical pilot study showing that administration of its Healight™ ultraviolet light A (UVA) endotracheal catheter delayed the time to development of ventilator-associated pneumonia (VAP) in a novel porcine model. Healight is the company’s…
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Ultraviolet Light Delivery Technology
More from InformationalMore posts in Informational »
- Controlling Biomanufacturing By Using UV Irradiation Against Unwanted Viral / Bacterial Species
- Luggate, NZ Drinking Water Upgrades To Include New UV Treatment Plant
- Environmental Breaches At Scotland Trust Properties Included Broken UV Lamps Used For Water Disinfection
- The Eyes Have It: Assessing Far-UVC’s Long-Term Ocular Impact
- Otago Community, NZ Plans Water Quality Infrastructure Upgrades Including UV Treatment Plant